
Opinion|Videos|March 18, 2024
Relapsed/Refractory Multiple Myeloma Overview
Author(s)Binod Dhakal, MD, MS
Binod Dhakal, MD, provides a high-level overview of relapsed/refractory multiple myeloma (R/R MM), including the clinical hallmarks, risk factors, and patient stratification.
Advertisement
Episodes in this series

Now Playing
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
3
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
4
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
5


















